Related Experiment Video

Updated: May 5, 2026

Serum and Plasma Copy Number Detection Using Real-time PCR
09:21

Serum and Plasma Copy Number Detection Using Real-time PCR

Published on: December 15, 2017

11.4K

Bioinformatics analysis reveals that CBX2 promotes enzalutamide resistance in prostate cancer

Zhu Wen1,2, Qinghua Li3, Guangmo Hu3

  • 1Department of Urology, The First People's Hospital of Hefei, Hefei, 230061, Anhui, China. urology_wen@163.com.

European Journal of Medical Research
|August 22, 2024
PubMed

Insights

Enzalutamide resistance in advanced prostate cancer (PCa) may be overcome by targeting CBX2. Silencing CBX2 increases P53 expression, offering a potential new therapeutic strategy for PCa patients resistant to Enzalutamide.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Advanced prostate cancer (PCa) treatment often involves Enzalutamide (Enz).
  • A significant number of patients develop resistance to Enz, limiting its efficacy.
  • Identifying mechanisms of Enz resistance is crucial for developing alternative therapies.

Purpose of the Study:

  • To investigate the role of CBX2 in mediating Enzalutamide resistance in prostate cancer.
  • To explore the impact of CBX2 on the P53 signaling pathway in PCa cells.
  • To evaluate CBX2 as a potential therapeutic target for Enz-resistant prostate cancer.

Main Methods:

  • Utilized Gene Expression Omnibus (GEO) databases to identify key genes involved in Enz resistance.
  • Investigated the effect of CBX2 on the P53 signaling pathway.
  • Employed small interfering RNA (siRNA) to silence CBX2 expression in LNCaP cells.

Main Results:

  • CBX2 was identified as a critical factor in Enzalutamide resistance.
  • CBX2 was found to inhibit the P53 signaling pathway.
  • Silencing CBX2 with siRNA resulted in increased P53 expression in LNCaP cells.

Conclusions:

  • CBX2 plays a significant role in prostate cancer Enzalutamide resistance.
  • Targeting CBX2 may restore sensitivity to Enzalutamide.
  • CBX2 represents a promising therapeutic target for patients with Enz-resistant prostate cancer.
Keywords:
CBX2EnzalutamidePCaProstate cancerResistance

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K
Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

6.8K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
84